http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
헬리코박터 관련 소화성궤양 환자에서 위산펌프길항제 사용이 요소호기검사 결과에 미치는 영향
옥주현 ( Ju Hyun Oak ),정우철 ( Woo Chul Chung ),정성훈 ( Sung Hoon Jung ),최강현 ( Kang Hyun Choi ),김은정 ( Eun Jung Kim ),강봉구 ( Bong Koo Kang ),강보라미 ( Bo Ra Mi Kang ),공시은 ( Si Eun Kong ),백창렬 ( Chang Nyol Paik ),이 대한소화기학회 2011 대한소화기학회지 Vol.57 No.1
Background/Aims: Revaprazan (Revanex(R)) is a novel proton pump inhibitor (PPI) that has a somewhat different effect on proton pump compared with the other PPI`s, also (called as `acid pump antagonist`). We aimed to examine the false negative rate of (13)C-urea breath test (UBT) in the patients with Helicobacter pylori (H. pylori) associated peptic ulcer disease who were treated with revaprazan and evaluate the anti-urease activity of revaprazan. Methods: Total 55 patients were enrolled in this study. They received EGD examination between January 2009 and December 2009 and diagnosed histologically as H. pylori associated peptic ulcer disease. All patients took revaprazan only. Three patients were excluded because of underlying chronic disease and inappropriate breath sampling. The remaining 52 patients had UBT at 0, 2 and 4 weeks of revaprazan use. After 2 weeks of the cessation of revaprazan, they had the fourth UBT. Results: At 2 and 4 weeks, the false negative rates of UBT were 5.8% and 23.1%, respectively (p=0.05). After 2 weeks of the cessation, the cases of the false negative result were five. Four out of five patients had prolonged negative results on two or three successive tests, and baseline (13)C difference value did not predict the false negative results. Conclusions: False negative results of UBT were common and increased with prolonged use of acid pump antagonist. As PPI, it had also anti-urease activity and most patients (47/52, 90.4%) reverted to positive results by 2 weeks after the cessation of taking the medication. (Korean J Gastroenterol 2011;57:8-13)